Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC)
G. Pentheroudakis
ANNALS OF ONCOLOGY (2020)
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Thierry Berghmans et al.
FRONTIERS IN MEDICINE (2020)
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Sun Min Lim et al.
IMMUNE NETWORK (2020)
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
S. Peters et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
Natasha B. Leigh et al.
LANCET RESPIRATORY MEDICINE (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
Toshirou Fukushima et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Martin Reck
IMMUNOTHERAPY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications
Wanyin Lim et al.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY (2018)
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
Karim Rihawi et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2017)
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Novello et al.
ANNALS OF ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer Treatment and Survivorship Statistics, 2014
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer
Eleazar Omar Macedo-Perez et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Establishing the Diagnosis of Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
M. Patricia Rivera et al.
CHEST (2013)
Clinical and Organizational Factors in the Initial Evaluation of Patients With Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
David E. Ost et al.
CHEST (2013)
Molecular Biology of Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Serge Patrick Nana-Sinkam et al.
CHEST (2013)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Patient-reported outcomes and the evolution of adverse event reporting in oncology
Andy Trotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer - A meta-analysis
C Delbaldo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Share Paper
